| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
To the editor
1. (A) Serum protein electrophoresis and immunofixation show IgM+κ type M proteinemia; (B)
FISH was performed using GLP P53 site-specific probes, and 25% of the
cells revealed one green signal, which was P53 gene deletion cells; (C)
FISH was performed using GLP 1q21 site-specific probes, and 23% of the
cells revealed three red signals, which were 1q21 site-expanded cells; (D) Typical double fusion signals were seen with the CCND1/IGH translocation probe.
|Figure 2. Patient's skin appearance during treatment: (A) Red rash on chest skin; (B) Hand skin ulceration with hyperpigmentation; (C) Skin peeling on the leg; (D) Skin peeling at the buttocks; (E, F) New skin with desquamation during recovery period.|
|Figure 3. Regimens: Course 1-2, Id (ixazomib 4 mg, dexamethasone 20 mg); Course 3, IRd (ixazomib 4 mg on Day 1, dexamethasone 15 mg on Days 1 and 2, lenalidomide 25 mg/d on Days 1-4); Course 4-5, PD (pomalidomide 4 mg, dexamethasone 15 mg); Course 6-12: PDC (pomalidomide 4 mg, dexamethasone 15 mg, cyclophosphamide 400 mg); Course 13: Vd (bortezomib 1mg, dexamethasone 15mg); Course 14: Vd (bortezomib 2mg, dexamethasone 15mg); BM: bone marrow.|